PMC:7696151 / 84184-84474
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 2483 | 6-12 | Disease | denotes | glioma | MESH:D005910 |
| 2531 | 153-161 | Species | denotes | patients | Tax:9606 |
| 2541 | 60-63 | Chemical | denotes | HCQ | MESH:D006886 |
| 2542 | 177-189 | Chemical | denotes | temozolomide | MESH:D000077204 |
| 2559 | 140-152 | Disease | denotes | glioblastoma | MESH:D005909 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T204 | 6-12 | Phenotype | denotes | glioma | http://purl.obolibrary.org/obo/HP_0009733 |
| T205 | 140-152 | Phenotype | denotes | glioblastoma | http://purl.obolibrary.org/obo/HP_0012174 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T537 | 30-213 | Sentence | denotes | The anticancer effect of free HCQ at 200–800 mg/day p.o. has been evaluated in two similar clinical trials on glioblastoma patients in concomitant temozolomide drugs and radiotherapy. |